 | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
John Maraganore is an American scientist, entrepreneur, and life sciences industry leader. [1] [2] [3] [4]
John was born in Chicago, Illinois, U.S. in 1962 to Greek immigrant parents. In 1984, he completed his B.A. from University of Chicago in Division of Biological Sciences. In 1985, he completed his M.S. from the University of Chicago in Department of Biochemistry and Molecular Biology. In 1986, Maraganore received his Ph.D. from the University of Chicago in Department of Biochemistry and Molecular Biology.
Maraganore started his career as a post-doctoral research scientist at Upjohn in Kalamazoo, Michigan, in 1985–86. During 1986–87, he was a senior scientist at Zymogenetics in Seattle, Washington. From 1987 to 1997, he was a senior scientist, group leader of thrombosis and hemostasis research, director of biological research, director of market and business development, and program executive at Biogen in Cambridge, Massachusetts. At Biogen, he invented bivalirudin, a direct-acting thrombin inhibitor, later commercialized in the U.S. as ANGIOMAXTM. In 1997, Maraganore joined Millennium Pharmaceuticals and was the general manager of their Biotherapeutics subsidiary until 1999. He then became vice-president of mergers, acquisitions, and strategic planning and led the acquisitions of Leukosite and Cor Therapeutics. In 2000, he was appointed senior vice-president of strategic product development. [5] [6] [7]
From 2002 until 2021, John served as the founding chief executive officer and a member of the board of directors at Alnylam Pharmaceuticals. At Alnylam, he led the company’s pioneering efforts to advance RNA interference therapeutics from early research through global approval and commercialization of the first four RNAi therapeutic medicines: ONPATTRO, GIVLAARI, OXLUMO, and LEQVIO. The fifth RNAi therapeutic medicine, AMVUTTRA, was approved in 2021. At Alnylam, he forged over 25 major partnerships with leading pharmaceutical and biotechnology companies, raised over $7.5 billion to fund the company’s research, development, manufacturing, and commercialization activities, and built $25 billion in market capitalization value. [8]
Since his departure at Alnylam, Maraganore is the principal of JMM Innovation, LLC, committed to the advancement of transformative medicines to patients through investment, board and strategic advisory services. He serves as a Venture Partner or Advisor to a number of investment firms including Arch Venture Partners, Atlas Ventures, Blackstone Life Sciences, and RTW Investments. He is a director of Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics, and Takeda Pharmaceuticals. He is also on the board of a number of privately held biotechnology companies, including Aera Therapeutics, Aitia, Hemab Therapeutics and Orbital Therapeutics. He is also a strategic advisor for a number of public and private biotechnology companies advancing biomedical innovation to patients.
Maraganore was the chair of the Biotechnology Innovation Organization also known as BIO from 2017 to 2019, was appointed chair emeritus in 2022, and serves as a member of BIO's board. In addition, he is a director of the Termeer Foundation, which advances the legacy of the late Henri Termeer, on the advisory board of Ariadne Labs, which focuses on health system innovations, a director of Nucleate, a student-led organization facilitating the formation of pioneering life sciences companies, and a director of CHDI Foundation, committed to accelerating therapeutics for Huntington’s Disease. He is also chair of the advisory board for n-Lorem, committed to advancing medicines for patients with nano-rare diseases, and a member of the MGH Research Institute's advisory council.
Finally, Maraganore is an active mentor to emerging leaders across the biotechnology industry. [9] [10] [11] [12] [13] [14]
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.
Gregory Stock is an American biophysicist, best-selling author, biotech entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA’s School of Medicine. His interests lie in the scientific and evolutionary as well as ethical, social and political implications of today's revolutions in the life sciences and in information technology and computers.
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
Ivor Royston is an American oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.
Christoph Westphal is an American biomedical businessman.
Jeremy Levin is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry.
Vicki L. Sato is a retired professor of management practice at Harvard Business School and a professor of the practice in the department of molecular and cell biology at Harvard University. Since 2021, she has been a member of the President’s Council of Advisors on Science and Technology (PCAST).
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Spotlight Innovation Inc. [STATUS CLOSED] was an American pharmaceutical holding company. The company maintained two subsidiaries: Caretta Therapeutics, Inc. and Celtic Biotech Iowa, Inc. Spotlight Innovation Inc. is based in Urbandale, Iowa and was publicly traded on the OTCQB marketplace under the stock ticker symbol, STLT.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.
Steven M. Paul is an American neuroscientist and pharmaceutical executive. Paul was the former CEO, president, and chairman of Karuna Therapeutics.
William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He was a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Iambic Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
BIOTECanada, previously the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.
George A. Scangos was a pharmaceutical executive and former chief executive officer of Vir Biotechnology from 2017 to 2023. Scangos was previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. Prior to joining industry, Scangos was a professor of biology at Johns Hopkins University.
{{cite web}}: |last2= has generic name (help)